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Abstract Worldwide, increasing numbers of patients are de-
veloping end-stage renal disease, and at present, the only treat-
ment options are dialysis or kidney transplantation. Dialysis is
associated with increased morbidity and mortality, poor life
quality and high economic costs. Transplantation is by far the
better option, but there are insufficient numbers of donor kid-
neys available. Therefore, there is an urgent need to explore
alternative approaches. In this review, we discuss how this
problem could potentially be addressed by using autologous
cells and appropriate scaffolds to develop ‘bioengineered’ kid-
neys for transplantation. In particular, we will highlight recent
breakthroughs in pluripotent stem cell biology that have led to
the development of autologous renal progenitor cells capable
of differentiating to all renal cell types and will discuss how
these cells could be combined with appropriate scaffolds to
develop a bioengineered kidney.
Keywords Induced pluripotent stem cells . Renal progenitor
cells . Kidney organoids . Decellularisation . Kidney
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Introduction
Over recent years, there has been an increasing interest in
developing stem cell-based regenerative medicine therapies
for patients with kidney disease. Stem cell therapies are al-
ready showing great promise in rodent models of acute and
chronic kidney disease [1], and several clinical trials are now
underway to assess the safety and efficacy of these novel
therapies in humans with kidney disease (see Table 1). It
should be noted, however, that while stem cell therapies
could be useful for ameliorating acute or chronic renal
injury, the consensus view is that they would be of little
benefit in the context of end-stage renal disease (ESRD).
The best treatment option for ESRD is kidney transplan-
tation, but the shortage of donor kidneys means that most
patients do not get offered a transplant, a situation which
has stimulated efforts to develop ‘bioengineered’ kidneys.
Whilst challenging, advances in biomaterials research and
stem cell biology, including cellular reprogramming tech-
nologies, means that bioengineered kidneys for patients
with ESRD could be possible in the future. For instance,
in 2013, a bioengineered rat kidney was constructed by
seeding rat neonatal kidney cells and human umbilical
cord endothelial cells on a decellularised adult rat kidney
scaffold [2••]. Importantly, these synthetic kidneys showed
some evidence of functionality and could produce ‘rudi-
mentary’ urine in rat hosts [2••]. For human patients, the
ideal components of a bioengineered kidney would be
autologous stem cells and non-immunogenic biomaterial
scaffolds, thus avoiding immune rejection and/or life-long
treatment with immunosuppressants. In this review, we will
discuss current progress towards the development of
bioengineered kidneys, with particular focus on the following
key issues: (i) the optimal source of autologous stem cells, (ii)
bioengineering strategies and (iii) safety aspects.
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Table 1 Clinical trials using stem cell therapies
Clinical trial name Clinical trial
identifier
Purpose Status Sponsor Estimated
study
completion
date
Pilot Feasibility Study of
Combined Kidney and
Hematopoietic Stem Cell
Transplantation to Cure
End-stage Renal Disease
NCT02176434 This pilot study of combined
kidney and hematopoietic stem
cell transplantation attempts to
establish a protocol to induce
immunological tolerance as a
new strategy to prevent renal
graft rejection. If successful, this
strategy would restore renal
function, while avoiding the
risks associated with long-term
standard anti-rejection therapy,
and would represent the first
option to cure end-stage renal
disease.
Recruiting University of Zurich August 2018
Mesenchymal Stem Cells
Transplantation in Patients With
Chronic Renal Failure Due to
Polycystic Kidney Disease
NCT02166489 This study was designed to
provide confirmation of safety
of mesenchymal stem cells
(MSCs) therapy in chronic renal
failure due to autosomal domi-
nant polycystic kidney disease
(ADPKD).
Completed Royan Institute, Tehran January 2016
Using Donor Stem Cells and
Alemtuzumab to Prevent Organ
Rejection in Kidney Transplant
Patients
NCT00183248 This study will evaluate treatment
of kidney transplant recipients
with alemtuzumab and other
immune system suppressing
medications with or without
infusions of bone marrow stem
cells from the kidney donor. The
purpose of this study is to find
out which strategy is more
effective in preventing organ
rejection and maintaining
patient health.
Completed University of Miami November
2009
Safety and Efficacy of Autologous
Bone Marrow Stem Cells for
Treating Chronic Renal Failure
NCT01152411 To evaluate the safety and efficacy
(to know / observe for Proof of
concept in five Indian patients) if
any, of autologous bone marrow
derived stem cells injected into
the Renal Artery in five (initially
five patients, can be increased to
ten patients after observing the
initial results) patients with
Chronic Renal Failure
Unknown International Stem Cell
Services Limited
Unknown
Induction of Donor Specific
Tolerance in Recipients of
Living Kidney Allografts by
Donor FCRx Infusion
NCT00497926 Use of a combination of an
Enriched Hematopoetic Stem
Cell Infusion and kidney
transplantation from the same
donor to try to avoid the need
for long-term anti-rejection drug
therapy. The desired result of
this study is to allow the body to
develop Btolerance^ to the
transplanted kidney.
Recruiting University of Louisville March 2030
Effect of BM-MSCs in DCD
Kidney Transplantation
NCT02561767 To determine the efficacy and safety
of allogeneic bone marrow-
derived mesenchymal stem cells
in kidney transplantation from
Chinese donation after citizen’s
death (DCD).
Not yet
Opened for
Recruitment
Sun Yat-Sen University October 2017
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Table 1 (continued)
Clinical trial name Clinical trial
identifier
Purpose Status Sponsor Estimated
study
completion
date
Induction of Donor Specific
Tolerance in Recipients of Live
Donor Kidney Allografts by
Donor Stem Cell Infusion
NCT00498160 Induction of Donor Specific
Tolerance in Recipients of
Kidney Allografts by Donor
Bone Marrow Cell Infusion
(Deceased Donors) and
Induction of Donor Specific
Tolerance in Recipients of Live
Donor Kidney Allografts by
Donor Stem Cell Infusion
Current University of Louisville December
2024
Mesenchymal Stem Cells After
Renal or Liver Transplantation
NCT01429038 To evaluate the safety and
tolerability of MSC
administration after liver or
kidney transplantation.
Recruiting University Hospital
of Liege
February 2017
Autologous Neo-Kidney Augment
(NKA) in Patients With Type 2
Diabetes and Chronic Kidney
Disease (CKD) (RMCL-CL001)
NCT02525263 A Phase II, Open-Label Safety and
Efficacy Study of an Autologous
Neo-Kidney Augment (NKA) in
Patients With Type 2 Diabetes
and Chronic Kidney Disease
(RMTX-CL001). NKA is made
from expanded autologous se-
lected renal cells (SRC) obtained
from the patient’s kidney biopsy.
All enrolled subjects will be
treated with up to two injections
of NKA at least 6 months apart.
Not yet
Opened for
Recruitment
RegenMed (Cayman)
Ltd.
January 2018
Induction Therapy With
AutologousMesenchymal Stem
Cells for Kidney Allografts
NCT00658073 To evaluate autologous MSCs as
an alternative for antibody
induction therapy in renal
transplantation
Completed Fuzhou General Hospital October 2010
Mesenchymal Stem Cell
Transplantation in the
Treatment of Chronic Allograft
Nephropathy
NCT00659620 The purpose of this study is to find
out MSC is more effective in
preventing organ rejection and
maintaining kidney function.
Completed Fuzhou General Hospital May 2010
Tolerance Induction in Living
Donor Kidney Transplantation
With Hematopoietic Stem Cell
Transplantation
NCT02199301 To evaluate the Tolerance
induction in KT recipients with
donor hematopoietic stem cell
transplantation (HSCT).
Recruiting Samsung Medical Center December
2017
MSC for Occlusive Disease of the
Kidney
NCT01840540 To determine the safety and
toxicity of intra-arterial infused
autologous adipose derived
mesenchymal stromal (stem)
cells in patients with vascular
occlusive disease of the kidney.
Opened Mayo Clinic April 2017
Autologous Bone Marrow
Derived Mesenchymal Stromal
Cells (BM-MSCs) in Patients
With Chronic Kidney Disease
(CKD)
NCT02195323 To provide confirmation of safety
of mesenchymal stem cells
(MSCs) therapy in chronic kid-
ney disease (CKD).
Completed Royan Institute January 2016
Kidney and Blood Stem Cell
Transplantation That Eliminates
Requirement for
Immunosuppressive Drugs
NCT00319657 To determine if blood stem cells
injected after kidney
transplantation will change the
immune system such that
immunosuppressive drugs can be
completely withdrawn. Patients
must have a healthy, completely
human leukocyte antigen
(HLA)-matched brother or sister
as the organ and stem cell donor.
Recruiting Stanford University July 2016
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Table 1 (continued)
Clinical trial name Clinical trial
identifier
Purpose Status Sponsor Estimated
study
completion
date
Mesenchymal Stem Cells In
Cisplatin-Induced Acute Renal
Failure In Patients With Solid
Organ Cancers (CIS/MSC08)
NCT01275612 To test the feasibility and safety of
systemic infusion of donor ex-
vivo expanded Mesenchymal
Stem Cells to repair the kidney
and improve function in patients
with solid organ cancers who
develop acute renal failure after
chemotherapy with cisplatin.
Recruiting Mario Negri Institute
for Pharmacological
Research
March 2017
Stem Cell Therapy for Patients
With Focal Segmental
Glomerulosclerosis (STEFOG)
NCT02693366 To analyze the safety, renal
function, metabolic disorders
and quality of life data in
patients with focal segmental
glomerulosclerosis treated with
endovascular infusion of bone
marrow derived mononuclear
cells.
Recruiting Universidade Federal
do Rio de Janeiro
June 2017
Effect of BM-MSCs on Early
Graft Function Recovery After
DCD Kidney Transplant.
NCT02563366 This study is designed to
investigate whether allogeneic
bone marrow-derived mesen-
chymal stem cells (BM-MSCs)
can promote function recovery
in patients with poor early graft
function after kidney transplan-
tation from Chinese Donation
after Citizen Death (DCD).
Not yet
Opened for
Recruitment
Sun Yat-Sen University December
2017
Mesenchymal Stem Cells Under
Basiliximab/Low Dose RATG
to Induce Renal Transplant
Tolerance
NCT00752479 To define the safety and biological/
mechanistic effect of the sys-
temic intravenous infusion of
syngeneic ex-vivo expanded
MSCs in living-related kidney
transplant recipients (one or two
HLA haplotype mismatches)
under basiliximab/low-dose
RATG induction therapy and
maintenance immunosuppres-
sive drugs with the ultimate ob-
jective to test the feasibility of
safely achieving graft tolerance
in a subsequent efficacy pilot
study.
Terminated Mario Negri Institute
for Pharmacological
Research
December
2013
Safety and Efficacy of BMMNC in
Patients With Chronic Renal
Failure
NCT01876017 Single center trial to check the
safety and efficacy of
Autologous Bone Marrow
derived Mono Nuclear Stem
Cell (BMMNCs) for the patient
with CRF
Recruiting Chaitanya Hospital,
Pune
December
2016
Study to Assess the Safety and
Effects of Autologous Adipose-
Derived Stromal Cells
Delivered in Patients With
Renal Failure
NCT01453816 An Open-label, Non-Randomised,
Multi-Center Study to Assess
the Safety and Effects of
Autologous Adipose-Derived
Stromal Cells Delivered Into the
Renal Artery and Intravenously
in Patients With Renal Failure
Unknown Ageless Regenerative
Institute
June 2015
Hypoxia and Inflammatory Injury
in Human Renovascular
Hypertension
NCT02266394 To determine if the MSC infusion
prior to percutaneous
transluminal renal angioplasty
with stenting (PTRA) further
enhances changes in single kid-
ney blood flow and restoration
Recruiting Mayo Clinic March 2019
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Sourcing Autologous Cells with Renal
Differentiation Potential
The kidney is one of the most complex organs in the human
body, consisting of more than 26 different cell types [3].Many
studies have analysed the potential of autologous cells for
treating kidney disease, both in preclinical models and in the
clinic. There has been particular focus on the use of cells that
either have their origin in the kidney or on cells of non-renal
origin that can nevertheless generate specialised renal cells
and can be easily sourced from the patient. Here, we give a
brief overview of the most well-studied autologous sources,
which include kidney-derived cells (KCs), mesenchymal
stromal/stem cells (MSCs), adipose-derived regenerative cells
(ADRCs) and induced pluripotent stem cells (iPSCs).
Adult Kidney Cells
A number of different approaches have been followed to
identify, isolate and characterise stem or progenitor cells
from human kidney biopsies, typically by investigating
clonogenicity, expression of stem cell markers, differentia-
tion potential and ability to ameliorate kidney injury
in vivo following administration into rodent disease models
[4–10]. One of the key tools has been the chimeric embryonic
kidney rudiment assay developed by Unbekandt and Davies
and its modified versions [11–14].With this in vitro approach,
the potential of the stem/progenitor cells to undergo renal
differentiation can be assessed by mixing the cells with disso-
ciated embryonic mouse kidney cells, which are then re-
aggregated to form a chimeric rudiment. Using this approach,
our group was able to show that kidney-derived stem cells
isolated from newborn mice have the potential to integrate
into embryonic kidney rudiments and contribute to develop-
ing nephron structures and glomeruli [15].
In human kidneys, NCAM, Tra-1-60 and CD133 have been
identified as putative stem/progenitor cell markers [16–21].
In vitro characterisation assays suggested that CD133+ cells
have a range of stem cell properties, including clonogenicity,
self-renewal and the potential to differentiate along the renal,
endothelial, adipogenic and osteogenic lineages [18–21].
Furthermore, administration of the cells into the tail vein of mice
with rhabdomyolysis-induced acute tubular injury, or
adriamycin-induced glomerular injury, resulted in amelioration
of histological damage and improved function [18, 20, 22, 23].
In these studies, the authors provided evidence that some of the
CD133+ KCs have the potential to integrate into the affected
renal structures, contributing to their repair.
An advantage of autologous CD133+ KCs is that they are
already committed to the renal lineage and would therefore be
expected to differentiate into specialised renal cells quite read-
ily. A major drawback, however, is that the number of healthy
KCs that could be retrieved from a renal biopsy from a patient
with ESRD would probably be too small to permit adequate
expansion in vitro; this is because the CD133+ KCs change
Table 1 (continued)
Clinical trial name Clinical trial
identifier
Purpose Status Sponsor Estimated
study
completion
date
of kidney function, as well as to
assess the relationship between
MSC dose and measures of
kidney function.
To Elucidate the Effect of
Mesenchymal StemCells on the
T Cell Repertoire of the Kidney
Transplant Patients
NCT02409940 Aim To investigate effect of MSCs
on immune cell repertoire in a
donor specific mediated
response.
Recruiting Postgraduate Institute of
Medical Education and
Research
December
2016
Mesenchymal Stem Cell
Transplantation in the
Treatment of Chronic Allograft
Nephropathy
NCT00659620 Mesenchymal Stem Cell (MSC)
has been shown to have immu-
nosuppressive and repairing
properties. the investigators will
infuse expanded MSC into pa-
tients who develop Chronic
Allograft Nephropathy. The
purpose of this study is to find
out MSC is more effective in
preventing organ rejection and
maintaining kidney function
Unknown Fuzhou General Hospital May 2010
Stem Cells and Kidney Disease – Clinical Trials; Source: www.ClinicalTrials.gov
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their phenotype and become senescent after ∼7 passages, thus
limiting their expansion capacity [18, 24, 25]. Furthermore,
there is no evidence that CD133+ KCs can generate all of the
26 different cell types in the kidney, so it is unlikely that they
could be used to generate a bioengineered kidney.
MSCs
MSCs can contribute to the regeneration and repair of various
organs. However, although it has been reported thatMSCs can
generate specialised renal cells [26, 27], more recent studies
have shown that the regenerative effects of MSCs in various
rodent kidney injury models are mediated by paracrine fac-
tors, including growth factors and extracellular vesicles
[28–30, 31•, 32–34], which can modulate the immune system
and suppress inflammation. For instance, a recent study has
shown that following intravenous injection of MSCs into a
rhabdomyolysis model of tubular injury, despite significant
improvement in renal histology and function, most cells were
located in the lungs or injured muscle, and none were present
in the kidney [31•]. Even following direct administration into
the kidney via the renal artery, MSCs were only transiently
located within the glomerular capillaries or interstitium and
did not differentiate into renal cells [32, 35–38]. Moreover,
MSCs that did persist in the kidney appeared to differentiate
into adipocytes within the glomeruli [39] and had an adverse
effect on renal health. Taken together, these studies show that
the therapeutic effects of MSCs are mediated by paracrine or
even endocrine factors, which probably improve renal health
by modulating the immune system. Consequently, MSCs
would be of little use in the development of a bioengineered
kidney.
ADRCs
ADRCs have recently become of interest as regenerative med-
icine therapies, not only because of their accessibility, but also
due to their efficacy in repairing tissue damage, including
ischaemia-induced injuries [40–44]. Recently, Cytori have de-
veloped a method for processing ADRCs under good labora-
tory practice (GLP) compliance by dissociating the adipose
tissue and enriching the ADRCs in a functionally closed sys-
tem using proprietary reagents [45, 46]. However, similarly to
MSCs, ADRCs appear to ameliorate injury by paracrine fac-
tors rather than by differentiating to replace damaged tissue
[40] and would be unable to generate the different types of
renal cells required to make a bioengineered kidney.
Thus, although therapeutic efficacy has been demonstrated
for KCs, MSCs and ADRCs in rodent kidney injury models,
there is no evidence that these cells can permanently integrate
into injured kidneys or differentiate in situ to replace all types
of damaged cells renal cells. Of note, for ADRCs or MSCs,
only a limited capacity to differentiate into epithelial cells in
vitro has been reported [47, 48]. This was supported by our
own work using the chimeric embryonic kidney rudiment as-
say, in which both human and murineMSCs demonstrated not
only failure to integrate and contribute to the development of
renal structures, but also negatively affected the formation of
nephron structures [49]. These observations indicate that
while MSCs and ADRCs could be effective autologous ther-
apies for acute or even early stage chronic kidney disease, they
would have no place in renal bioengineering strategies to treat
ESRD patients. Adult KCs appear to have at least some renal
differentiation potential in vitro, albeit limited, but autologous
sourcing would be problematic, especially for patients with
ESRD where very little healthy renal tissue remains.
iPSCs
Several studies have previously shown that murine embryonic
stem cell (ESC)-derived mesodermal cells can be directed to
differentiate into a range of renal cell types. This was achieved
using various techniques, including co-culture methods
with embryonic spinal cord, the kidney rudiment assay,
or after injection ex vivo or in vivo into newborn mouse
kidneys [13, 50–53]. Although encouraging, a major draw-
back with ESCs is that they are not autologous and would
therefore induce an immune response if incorporated into
a bioengineered kidney. However, the development by
Yamanaka and colleagues of a strategy to reprogramme
adult cells into ESC-like induced pluripotent stem cells
(iPSCs) [54] means that autologous pluripotent stem cells
are now available for personalised cell therapies. The original
cocktail of Yamanaka factors, which consisted of Oct3/4,
Sox2, Klf4 and c-myc, has since been optimised to replace
the two oncogenes, c-myc and Klf4 [55], thus making the
iPSCs less tumourigenic. Furthermore, the use of ‘non-inte-
grating’ methods to introduce the reprogramming factors has
circumvented the need for lenti- or retroviral vectors [56],
which pose safety issues due to the fact that they integrate into
the genome and can induce oncogenic transformation [57].
Over the last few years, a number of groups have been able
to develop protocols to direct the differentiation of iPSCs to
nephron progenitor cells (capable of generating cells of the
nephron; also known as ‘metanephric mesenchyme’) and re-
nal progenitor cells (RPCs) (capable of generating cells of the
nephron, collecting tubules and interstitium). Seminal work in
this field came from the Nishinakamura group, who, using
information gleaned from the mouse embryo, designed a 3-
stage differentiation protocol for directing the differentiation
of ESCs or iPSCs to nephron progenitors [58••]. This was
achieved by incubating ESCs or iPSCs with various growth
factors, including Activin, Bmp4, FGF9 and the Wnt agonist
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CHIR99021, at specific time points to mimic the temporal
regulation of mesoderm differentiation in vivo. Apart from
Nishinakamura, various other groups have described proto-
cols for directing the differentiation of iPSCs into the renal
lineage [58••, 59–62, 63••, 64••, 65, 66, 67•], with recent
studies by the Little and Bonventre groups showing that
iPSC-derived RPCs can self-organise into kidney organoids
containing glomerular and tubular structures with evidence
of transport function and endothelial cell integration [63••,
64••, 68]. These studies present an exciting breakthrough in
the field because for the first time, they show that all cells
of the kidney can be generated from an autologous cell
source, potentially opening the door to the development
of bioengineered kidneys (Fig. 1). In the next section, we
will discuss three strategies whereby iPSC-derived RPCs
could be used for this purpose.
Bioengineering Strategies
Here, we will focus on the following three strategies that have
potential for developing bioengineered kidneys in the future:
(i) self-organisation of RPCs to generate renal organoids, (ii)
seeding of RPCs into decellularised kidney scaffolds and (iii)
3D bioprinting of RPCs and synthetic matrices.
RPC-Derived Organoids
Since the 1990s, various groups have explored the possibility
of transplanting kidney rudiments derived from rodent, pig
and human foetal kidneys into adult hosts. In most cases, the
rudiments showed some evidence of growth and functionality,
irrespective of whether they were transplanted under the
kidney capsule [69, 70], into the kidney parenchyma [71],
near the abdominal aorta [72] or into the omentum [70,
73, 74]. However, there are several technical problems
with rudiment transplantation that would prevent this approach
from being used in the clinic. Firstly, the rudiments would
be non-autologous and therefore immunogenic. Secondly,
in these early studies, the rudiments did not connect to
the host’s ureter, leading in some cases to the development
of hydronephrosis. Thirdly, although the rudiments grew in
their new hosts, they did not mature beyond a neonatal
Fig. 1 Schematic diagram
showing 3 potential methods for
making bioengineered kidneys
using autologous cells. 1 iPSC-
derived RPCs and endothelial
cells self-organise in vitro to
generate renal organoids. 2 iPSC-
derived RPCs and endothelial
cells are introduced into
decellularised human or pig kid-
neys via the renal artery
(endothelial cells) and ureter
(RPCs). 3 iPSC-derived RPCs,
endothelial cells and an
appropriate matrix are printed
according to a computer-
generated organ ‘blueprint’
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stage and their filtering capacity was only equivalent to
2 % of that of an adult kidney [72, 75].
With the advancements in generating iPSC-derived RPCs,
the first of these problems could now be overcome. As
discussed above, under the appropriate culture conditions,
iPSC-derived RPCs can give rise to both metanephric mesen-
chyme (the nephron progenitors) and ureteric bud (the progen-
itors of the collecting tubules and ureter) [63••, 64••].
Remarkably, it was shown that these two primordial cell types
could differentiate appropriately in vitro and self-organise to
form 3D organoids comprising nephrons complete with glo-
meruli, proximal and distal tubules and loops of Henle, which
were associated with ureteric bud-derived collecting tubules.
These organoids also had iPSC-derived renal interstitial and
endothelial cells [64••].
However, the problems of connecting the organoids to the
host’s urine excretory system and of promoting their matura-
tion so that they can function as adult kidneys are yet to be
overcome. Some progress has been made towards connecting
transplanted kidney rudiments to the host’s ureter, with one
study showing that the ureters of transplanted rat kidney rudi-
ments can be anastomosed to the host’s urinary system [72],
and more recently, the group of Yokoo has been able to con-
nect pig kidney rudiment ureters with a bladder generated
from a transplanted cloaca [76]. Whilst impressive, these ap-
proaches would not be suitable for transplanted organoids as
these RPC-derived structures lack a ureter (Fig. 1).
Decellularization of Kidney Scaffolds
Decellularization of animal or human organs in combi-
nation with re-cellularization using autologous progeni-
tor and endothelial cells is the most promising approach
to generating bioengineered organs ex vivo and seems to offer
the quickest route to clinical applications [77–79]. During the
decellularization process, the cellular compartment of a given
organ is removed through delivery of a detergent-based
solution via the innate vasculature throughout the organ
parenchyma. This approach has been successfully used to
generate a bioengineered airway consisting of a decellularised
cadaveric trachea seeded with autologous MSC-derived
chondrocytes and bronchial epithelial cells derived from a
patient with bronchial stenosis. The airway was used to re-
place the stenosed bronchus and the patient had a very good
outcome and, importantly, did not require immunosuppressant
therapy [80, 81]. In the case of the kidney, a number of
decellularization protocols have been established in rodent,
pig, rhesus monkey and human kidneys [2••, 82, 83•,
84–87]. These protocols involve the use of detergents or en-
zymes which are perfused in an antegrade fashion from the
renal artery through the kidney vasculature (and sometimes
through the ureter) [83•, 85], thus removing all cells [67•,
88, 89]. Importantly, the extracellular matrix (ECM) that re-
mains after the decellularization process maintains the delicate
glomerular and tubular structures as well as the vascular tree
of the kidney. Furthermore, the ECM is able to modulate the
phenotype of seeded progenitor cells, which express renal
developmental genes in response [86, 90, 91]. In addition,
immunogenicity is reduced since major immunogenicity anti-
gens are lost after decellularization [83•]. This raises the pos-
sibility that decellularised kidneys from other species could be
used as a source of scaffold for transplantation, the advantage
being that such kidneys would be in pristine condition, where-
as human kidneys deemed unsuitable for transplantation could
have structural damage. The pig is particularly attractive be-
cause the size andmicroarchitecture of pig and human kidneys
are similar [92].
Following decellularisation of the kidney scaffold, the next
challenge is to repopulate with renal cells and endothelial
cells. Most studies have focused on the rat kidney as a model
to study the effects of re-cellularisation on cell distribution and
function, using various cell combinations, including mouse
ESCs [86, 93, 94], human iPSC-derived endothelial cells with
human renal cortical tubular epithelial cells [95], rat aorta
endothelial with rat epithelial tubular cells [96] and human
umbilical vascular endothelial cells with rat neonatal kidney
cells [2••]. Other groups have reported re-cellularisation of
decellularised mouse, pig and rhesus monkey kidneys using
human kidney cells, foetal rhesus monkey kidney cells or
ESCs [2••, 82, 87, 94, 97]. Interestingly, ESCs seeded into
the kidney scaffolds have been shown to populate the matrix
with evidence of site-appropriate differentiation, indicating
that the ECM of the decellularised kidneys can instruct the
ESCs to differentiate into renal and vascular elements of the
kidney [86, 93, 94].
Research in this field is still ongoing, and currently, optimal
re-cellularisation techniques are being developed. Three major
challenges are being recognised: the requirement for an autol-
ogous cell type that can differentiate into both endothelial and
specialised kidney cells, a strategy for achieving complete re-
cellularisation and the application of a transrenal pressure gra-
dient. Previous studies have explored the use of endothelial
and renal progenitor cells from various sources [2••, 95, 96],
but it is clear that iPSC-derived RPCs and endothelial cells
present the best route forward due to the fact that they are
autologous and RPCs can generate all cell types of the neph-
rons and collecting tubules.
In order to re-cellularise the kidney, Caralt and colleagues
performed perfusion experiments separately by injecting
either human iPSC-derived endothelial cells or an immortalised
human renal cortical tubular epithelial cell line via the renal
artery. While excellent vascular repopulation by the endothelial
cells was observed, it was found that after 24 h, only 50 % of
the renal tubules were re-cellularised by the kidney cells [95].
Using a different approach involving perfusion of rat
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endothelial cells and tubule epithelial cells via the renal artery
(antegrade) and ureter (retrograde), respectively, it was shown
that the vascular network could be efficiently repopulated by
the endothelial cells, which were able to survive and proliferate,
while the tubular epithelial cells failed to populate the kidney
scaffold sufficiently. This study also involved the use of a spe-
cifically designed bioreactor which allowed the application of a
transrenal pressure gradient during the seeding procedure. It
was found that the arterial pressure increased in the kidneys
repopulated with endothelial cells, indicating functionality of
the endothelial cells through changes in flow resistance [96].
The most promising demonstration of re-populating
decellularised kidneys has been reported by the Ott group
who successfully managed to seed both human umbilical vas-
cular endothelial cells and rat neonatal kidney cells into
decellularised rat kidneys. They combined antegrade seeding
of endothelial cells with retrograde seeding of the kid-
ney cells under the application of a transrenal pressure
gradient in a special bioreactor. The cells populated half
of the glomeruli and nephron structures across the kid-
ney scaffold and expressed tissue-specific markers.
Furthermore, the repopulated kidneys were assessed for
their functionality ex vivo and displayed some degree of
filtration capacity, whereas the decellularised kidneys
did not. Of note, when the re-cellularised kidneys were
transplanted orthotopically into recipient rats, it was
found that urine-like solution could be produced, albeit
at lower levels than in native kidneys [2••].
Taken together, while highly promising, these results dem-
onstrate that further optimisation is needed to generate fully
functional bioengineered kidneys using decellularised scaf-
folds. Specifically, one of the main challenges is to achieve
the full repopulation of the decellularised kidney scaffold in an
organotypic way, resulting in correct spatial distribution of
appropriately differentiated renal and endothelial cells which
physiologically interact to perform the filtration function of
the kidney (Fig. 1). As discussed below, this could potentially
be overcome by using a bioprinting approach that simulta-
neously prints the cells along with an appropriate synthetic
scaffold, thereby circumventing the repopulation problem.
3D Bioprinting
Three-dimensional (3D) bioprinting is an emerging technolo-
gy that facilitates the layer-by-layer precise positioning of bi-
ological materials, biochemicals and living cells, with spatial
control of the placement of functional components [98]. 3D
printing technology offers alternative approaches to generat-
ing organotypic scaffolds for bioengineering of organs. A
pioneering study by the group of Atala showed that 3D
bioprinting could be used to generate a biodegradable scaffold
of a human bladder. These bioengineered bladders were
seeded with autologous urothelial and muscle cells and were
transplanted into seven patients with non-functional bladders
[99]. 3D bioprinting of various other tissues, such as vessels
and tracheal grafts, has also been achieved [100, 101].
However, it should be noted that the aforementioned tissues
and organs are relatively simple structures, whereas the kidney
is much more complex, containing approximately one million
nephrons. For this reason, the possibility of engineering a 3D-
bioprinted kidney is currently beyond our capabilities.
However, with further advances in this technology, it could
be possible to combine 3D printing of the kidney scaffold with
autologous RPCs and endothelial cells in order to generate
personalised kidneys for patients with ESRD (Fig. 1).
Interestingly, Organovo Inc. has recently presented a 3D
bioprinted model of ‘kidney proximal tubular tissue’. The
3D tissue, which consisted of proximal tubule cells, renal in-
terstitial cells and endothelial networks, could be maintained
in culture for up to two weeks [102].
Safety Issues
The main safety issues concerning bioengineered kidneys re-
late to the cell types used to repopulate the kidney, and the
source of the renal scaffold.
Cell-Related Safety Issues
As previously mentioned, iPSC-derived RPCs are most prom-
ising due to the fact that they can generate all cell types within
the kidney [63••, 64••]. However, pluripotent cells such as
iPSCs pose particular risks due to their propensity to form
teratomas, or even teratocarcinomas. It would therefore be
very important to ensure that the RPC population used in the
therapy did not contain any undifferentiated iPSCs. Before
transplanting bioengineered kidneys into man, it would also
be crucial to track their fate in preclinical models in order to
assess whether they migrate to distant organs and tissues
where they could potentially maldifferentiate or form tumours
[103]. Particular caution would be needed with immunosup-
pressed transplant patients, for it is known that immunosup-
pressant therapy significantly increases the risk of tumour for-
mation [104]. The use of autologous cells should hopefully
obviate the need for immunosuppressants, though they might
still be required if the source of scaffold was found to be
immunogenic. Despite the concerns related to the use of plu-
ripotent cell therapies, a number of clinical trials are in prog-
ress to assess their safety in the treatment of particular dis-
eases, such as the use of ESC-derived retinal pigment epithe-
lial cells in patients with age-related macular degeneration
[105]. To date, there have been no reports of recipients of
ESC-based therapies developing tumours, which suggest that
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if sufficient care is taken to ensure that the administered pop-
ulation has a normal karyotype, has been scaled up under
conditions of Good Manufacturing Practice, and is not con-
taminated with undifferentiated cells, the therapy is likely to
be safe.
Scaffold-Related Safety Issues
Decellularised scaffolds are unlikely to pose particular safety
issues because they are composed of native ECM. It would be
expected that the ECM would be degraded over time and
replaced with new ECM derived from the cells used to repop-
ulate the scaffold. A potential safety issue might arise if the
rate of ECM degradation was faster than that of new ECM
deposition, as this would be expected to affect the integrity of
the scaffold. Of note, the patient who received a bioengineered
airway generated from a decellularised scaffold remained well
at 5 years follow-up [80], suggesting that this could be a safe
approach, at least for tissues and organs with simple struc-
tures. However, the number of clinical studies conducted to
date are too few to confirm the safety and feasibility of this
approach [106]. Synthetic and/or bio-printed substrates would
be expected to pose more safety issues than bioengineered
organs comprising decellularised scaffolds simply because
their composition would be different than that of native scaf-
folds. For this reason, it could be difficult to predict how they
might interact with the host over the short or long term. A
recent report indicating a high incidence of death (6 out of 8)
in patients transplanted with synthetic tracheas [107] demon-
strates the need for this field to progress cautiously within a
robust regulatory framework.
Conclusions
In the last few years, tremendous progress has been made
towards the development of autologous cells for kidney bio-
engineering. The key advance has been the development of
RPCs derived from pluripotent stem cells (i.e. ESCs and
iPSCs) that can generate all cells of the nephron and collecting
tubules and have the ability to self-organise in vitro to form
renal organoids [63••, 64••]. It is unlikely that these organoids
will be useful as a therapy to directly treat patients with ESRD
because based on previous studies with rudiment transplants
[72], they would probably not mature sufficiently and would
not be connected with the host’s urinary excretory system.
Nevertheless, renal organoids present an excellent model sys-
tem for understanding kidney development and disease and
for drug screening programmes. In regard to therapy, instead
of transplanting renal organoids, a more promising approach
would be to use iPSC-derived RPCs and endothelial cells to
recellularise kidney scaffolds derived either from human
donor kidneys or pig kidneys. Much progress has been made
towards this goal [2••], but the key challenge that still needs to
be overcome is that of repopulating the nephrons and ensuring
that the cells differentiate and function appropriately accord-
ing to their position along the renal tubule. 3D bioprinting
could potentially solve this problem, but despite the signifi-
cant and exciting advances that have been made, printing
complex organs like the kidney will not be happening soon,
as the technology requires a considerable amount of time to
evolve.
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